Cannabidiol has been primarily indicated for the treatment of neurological and psychiatric conditions. The recommended use, dosage, and duration of treatment must be determined by a physician with an active registration with the CFM (Federal Council of Medicine).

According to RDC No. 327/2019, the indication and method of use of cannabis products are the responsibility of the attending physician.

Any physician with an active registration with the CFM can prescribe cannabis products in Brazil using a white Special Control prescription form. The recommended use, dosage, and duration of treatment must be explained to the patient at the time of prescription.

Pharmacological safety, acute toxicity, and genotoxicity tests have been completed and confirm its safety. The test results are available in the Medical Area.

Gastrointestinal adverse events such as nausea, diarrhea, or constipation, loss of appetite, and gastric intolerance are the most common. Drowsiness, lethargy, dizziness, sedation, and fatigue have also been described in the scientific literature in association with cannabidiol use. When present, adverse effects are usually mild to moderate. In the event of adverse reactions or any changes, the prescribing physician should be consulted and use of the product discontinued.

The product contains no artificial flavorings or flavoring agents and has no taste or odor.